Paper: IDH mutations sensitize cells to PARP inhibition

Researchers at Yale University School of Medicine are planning an NCI-sponsored clinical trial to test their hypothesis that cancer patients with isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations will have better outcomes if treated with a PARP inhibitor rather than an IDH1/2 inhibitor. The team believes IDH mutations may sensitize patients to synthetic lethality. The proposed basket trial's principal investigator, Yale Professor Ranjit Bindra, told BioCentury that the study will enroll about 50 patients with IDH1/2 mutant tumors independent of tumor histology.

Bindra said the Phase II trial will evaluate Lynparza olaparib in patients with IDH1/2-mutant tumors. Enrollment is slated to begin this fall. He said AstraZeneca plc (LSE:AZN; NYSE:AZN) has agreed to provide Lynparza for the study...